A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799).



Status:Recruiting
Conditions:Lung Cancer, Lung Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/29/2019
Start Date:October 19, 2018
End Date:March 14, 2022
Contact:Toll Free Number
Email:Trialsites@merck.com
Phone:1-888-577-8839

Use our guide to learn which trials are right for you!

A Phase 2 Trial of Pembrolizumab (MK-3475) in Combination With Platinum Doublet Chemotherapy and Radiotherapy for Participants With Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-799).

This is a trial in adult participants with unresectable, locally advanced, Stage III
non-small cell lung cancer (NSCLC) treated with pembrolizumab in combination with platinum
doublet chemotherapy and standard thoracic radiotherapy followed by pembrolizumab
monotherapy. The primary hypothesis of the trial is that within each platinum doublet
chemotherapy cohort, the percentage of participants who develop Grade 3 or higher pneumonitis
is ≤10%.


Inclusion Criteria:

- Male/female participants, who are at least 18 years of age on the day of signing
informed consent with previously untreated, unresectable, pathologically confirmed
NSCLC and Stage IIIA, IIIB or IIIC NSCLC by American Joint Committee on Cancer Version
8.

- No evidence of metastatic disease by whole body positron emission tomography/computed
tomography (PET/ CT) scan, diagnostic quality CT scan, and brain imaging.

- Have measurable disease per RECIST 1.1 as assessed by the local site
investigator/radiology.

- Have provided tumor tissue sample (core, incisional, or excisional biopsy).

- Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.

- Have adequate pulmonary function test (PFT)

- Have adequate organ function

- A male participant must agree to use contraception through the end of treatment and
refrain from donating sperm during this period.

- A female participant is eligible to participate if she is not pregnant, not
breastfeeding, and if participant is a woman of childbearing potential (WOCBP), agrees
to follow the contraceptive guidance as provided in the protocol through the end of
treatment.

Exclusion Criteria:

- A WOCBP who has a positive urine pregnancy test within 72 hours prior to treatment
allocation

- Has small cell lung cancer.

- Has had documented weight loss >10% in the preceding 3 months.

- Participants whose radiation treatment plans are likely to encompass a volume of whole
lung receiving >20 Gy in total (V20) of more than 31% of lung volume.

- Has received prior radiotherapy to the thorax, including radiotherapy to the esophagus
or for breast cancer.

- Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
(programmed cell death protein 1 [PD-1] and its ligands, programmed cell death ligand
1 (PD-L1) and programmed cell death ligand 2 [PD-L2]) or with an agent directed to
another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137).

- Has received a live vaccine within 30 days prior to the first dose of study drug.

- Has had an allogenic tissue/solid organ transplant.

- Is currently participating in or has participated in a study of an investigational
agent or has used an investigational device within 4 weeks prior to the first dose of
study treatment.

- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
(in dosing exceeding 10 mg prednisone daily or equivalent) or any other form of
immunosuppressive therapy within 7 days prior the first dose of study drug.

- Has a known additional malignancy that is progressing or has required active treatment
within the past 5 years.

- Has severe hypersensitivity (Grade 3 or higher) to pembrolizumab and/or any of its
excipients.

- Has a known severe hypersensitivity (Grade 3 or higher) to any of the study
chemotherapy agents and/or to any of their excipients.

- Has an active autoimmune disease that has required systemic treatment in past 2 years
(ie, with use of disease modifying agents, corticosteroids or immunosuppressive
drugs).

- Has a history of (non-infectious) pneumonitis/interstitial lung disease that required
steroids or has current pneumonitis/interstitial lung disease that requires steroids.

- Has an active infection requiring systemic therapy.

- Has a known history of human immunodeficiency virus (HIV) infection. HIV testing is
not required unless mandated by local health authority.

- Has a known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg]
reactive) or known active hepatitis C virus (defined as HCV RNA [qualitative] is
detected) infection.

- Has a known history of active tuberculosis (TB; Bacillus tuberculosis).

- Has a history or current evidence of any condition, therapy, or laboratory abnormality
that might confound the results of the study, interfere with the participant's
participation for the full duration of the study, or is not in the best interest of
the participant to participate, in the opinion of the treating investigator.

- Has a known psychiatric or substance abuse disorder that would interfere with
cooperating with the requirements of the study.

- Is pregnant or breastfeeding or expecting to conceive or father children within the
projected duration of the study through the end of treatment.
We found this trial at
11
sites
Santa Rosa, California 95403
Phone: 707-521-3830
?
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
5 Fleet Street
Blacktown, New South Wales 2151
Phone: +61403170371
?
mi
from
Blacktown,
Click here to add this to my saved trials
2799 W Grand Blvd
Detroit, Michigan 48202
(313) 916-2600
Phone: 313-916-2635
Henry Ford Hospital Founded in 1915 by auto pioneer Henry Ford and now one of...
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Evanston, Illinois 60201
Phone: 847-570-2109
?
mi
from
Evanston, IL
Click here to add this to my saved trials
11050 Parkview Circle
Fort Wayne, Indiana 46845
Phone: 833-724-8356
?
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Grand Island, Nebraska 68803
Phone: 308-398-5450
?
mi
from
Grand Island, NE
Click here to add this to my saved trials
New Brunswick, New Jersey 08903
Phone: 732-235-6048
?
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19111
Phone: 215-728-5862
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
1309 W 17th Street
Sioux Falls, South Dakota 57104
(605) 328-8000
Phone: 605-328-8000
Sanford Cancer Center-Oncology Clinic Sanford Health is an integrated health system headquartered in the Dakotas...
?
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Tulsa, Oklahoma 74133
Phone: 918-286-5448
?
mi
from
Tulsa, OK
Click here to add this to my saved trials
Worcester, Massachusetts 01605
Phone: 508-334-5539
?
mi
from
Worcester, MA
Click here to add this to my saved trials